MARKET

BIVI

BIVI

BioVie
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.88
-0.25
-2.74%
Closed 16:00 12/03 EST
OPEN
8.99
PREV CLOSE
9.13
HIGH
9.21
LOW
8.50
VOLUME
17.27K
TURNOVER
--
52 WEEK HIGH
34.54
52 WEEK LOW
2.200
MARKET CAP
123.58M
P/E (TTM)
-1.1790
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
BioVie Interview to Air on Bloomberg International on the RedChip Money Report
BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today announced an interview with Terren Peizer, Chairman and Chief Executive Officer, will air on The RedChip Money Report television program this Sunday November 1st. The RedChip Money Report airs in 100 million homes on Sundays at 6 p.m. local time in every country in Europe on Bloomberg International.
GlobeNewswire · 10/30 12:00
BioVie to Participate in B. Riley Securities Liver Disease Therapeutics Day on October 29, 2020
BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today announced that it will participate in the B. Riley Securities' Liver Disease Therapeutics Day 2020 on Thursday, October 29, 2020 at 11:00 a.m. ET.
GlobeNewswire · 10/29 12:00
Insider Weekends: Director Of Selecta Biosciences Purchases Over Half A Million Dollars' Worth Of Stock
Insider buying decreased once again last week.Notable Insider Buys: Gossamer Bio, Inc., Selecta Biosciences, Inc., Citigroup Inc., Loop Industries, Inc., and BioVie Inc.Notable Insider Sells: Okta, Inc., Paycom Software, Inc., Apple Inc., salesforce.com, inc., and Workday, Inc.
Seekingalpha · 10/19 10:04
U.S. IPO Week Ahead: Healthcare, Solar Panels, And Chinese Retail In A 9 IPO Week
Five biotechs, two medical device makers, a solar panel mounting manufacturer, and a Chinese retailer are scheduled to raise $2.0 billion in the week ahead.Several companies could join the IPO calendar early in the week, including McAfee and Datto Holding.Street research is expected for 15 companies.The lock-up for Renalytix AI will be expiring on Thursday, 10/15.
Seekingalpha · 10/11 20:55
BioVie Announces Closing of Public Offering of Common Stock
BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today announced that it has closed its previously announced underwritten public offering of Class A common stock, including the full exercise of the underwriters' overallotment option, resulting in aggregate gross proceeds to the Company of $18.0 million. The Class A common stock sold in the offering has been approved for listing on the Nasdaq Capital Market under the symbol "BIVI." After deducting underwriting fees and other offering expenses payable by the Company, the net proceeds to the Company were approximately $15.8 million.
GlobeNewswire · 09/23 12:00
BioVie Announces Closing of Public Offering of Common Stock
Includes Full Exercise of Underwriters’ Overallotment OptionSANTA MONICA, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today announced that it has closed
GlobeNewswire · 09/23 12:00
BioVie to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit
SANTA MONICA, CA / ACCESSWIRE / September 21, 2020 / BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today announced that Jonathan Adams, the Company's President & COO, will present at the Oppenheimer Fall Healthcare Life Sciences & Medtech Summit on Monday, September 21, 2020 at 1:40 p.m. ET.
ACCESSWIRE · 09/21 11:00
BioVie to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit
SANTA MONICA, CA / ACCESSWIRE / September 21, 2020 / BioVie Inc.
ACCESSWIRE · 09/21 11:00
More
Forecast
EPSBVPSCFPS
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BIVI. Analyze the recent business situations of BioVie through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Institutional Holdings
Institutions: 1
Institutional Holdings: 100.00K
% Owned: 0.72%
Shares Outstanding: 13.92M
TypeInstitutionsShares
Increased
0
0
New
0
0
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.41%
Pharmaceuticals & Medical Research
+0.49%
Key Executives
President/Chief Operating Officer
Jonathan Adams
Chief Executive Officer/Director
Terren Peizer
Chief Financial Officer/Secretary
J. Wendy Kim
Chief Scientific Officer
Penelope Markham
Other
Patrick Yeramian
Director
Richard Berman
Director
Steven Gorlin
Director
Robert Hariri
Director
Rajah Menon
Director
Sigmund Rogich
Independent Director
Hari Kumar
Independent Director
James Lang
Independent Director
Michael Sherman
Independent Director
Mina Sooch
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BIVI
BioVie, Inc., formerly NanoAntibiotics, Inc., is a clinical-stage company. The Company is focused on developing and commercializing BIV201, a novel approach to the treatment of ascites due to chronic liver cirrhosis. The Company is developing BIV201 for alleviating the portal hypertension and correcting splanchnic vasodilation, thereby increasing effective blood volume and reducing the signals to the kidneys to retain excess salt and water. In March 2017, the Company initiated a Phase II a United States clinical trial of BIV201. The Company’s subsidiary is LAT Pharma LLC.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of BioVie Inc stock information, including NASDAQ:BIVI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIVI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BIVI stock methods without spending real money on the virtual paper trading platform.